Pfizer and Astellas' Xtandi combo extends survival in early prostate cancer setting

Xtandi is approved in over 80 countries, including the U.S., EU, and Japan

IMCD opens life science laboratory hub in Shanghai

The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms

EMA and HMA to strengthen Anti-D Immunoglobulin supply chain

These medicines are essential in preventing RhD immunisation during pregnancy

atai and Beckley Psytech announce positive Phase 2b results for treatment-resistant depression

atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.

argenx advances clinical development of agonist antibody for myasthenic syndromes

ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept

Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen US footprint

The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market

WuXi XDC announces mechanical completion of Singapore site

The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025

India exports US$ 4,961 million pharmaceutical during April–May 2025: Pharmexcil

Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future

Lupin carves out LupinLife Consumer Healthcare

Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Gel

Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery